U.S. Market Expected to Grow from USD 0.81 Billion to USD 3.31 Billion by 2035; Europe Market Forecast to Reach USD 2.18 Billion as Advanced Therapy Research Expands.Austin, United States, June 09, ...

Viral vectors are engineered viruses that are used to deliver genetic material into cells for various applications, such as gene therapy, vaccine development, and biotechnology research. These viruses ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

U.S.-based researchers have developed a portfolio of peptide ligands for purifying viral vectors for gene therapies and have launched a company that develops affinity technologies for ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, today announced the expansion of its ...

For instance, the team discovered that AAV4, a viral vector that has not been studied extensively, efficiently delivers its genetic payload to endothelial cells in blood vessels and beta cells in the ...

Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

Viral vectors introduce genes and gene editing sequences into cells, and are a popular platform for gene therapy due to their safety and efficacy features. Adeno-associated viral (AAV) vectors in ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...